With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — ...

Johnson & Johnson has announced that its Darzalex Faspro-based regimen (daratumumab and hyaluronidase, in combination with ...

Biogen’s litifilimab has received Breakthrough Therapy Designation from the US FDA to treat cutaneous lupus erythematosus ...

Alzheimer’s disease (AD) continues to be one of the most challenging conditions facing patients, families and healthcare ...

Skyhawk Therapeutics has announced positive interim results from its phase 1 trial of SKY-0515, an investigational treatment ...

Boehringer Ingelheim and Simcere have announced a new license and collaboration agreement for the development of SIM0709, a ...

The current landscape The landscape of dementia clinical trials in Europe is focused on AD, the most common form of dementia.

Grounded in data-driven human insights and representing the perspectives of both patients and HCPs, medical affairs can ...

AstraZeneca and CSPC Pharmaceuticals have announced a new collaboration agreement for the development of therapies for obesity and type 2 diabetes.

Genentech has doubled its initial investment in a new manufacturing facility located in Holly Springs, North Carolina, bringing investment in the project to around $2bn.

AstraZeneca has announced a $15bn investment in China by 2030 to expand manufacturing and R&D.

GC Therapeutics has appointed Kate Haviland as Board Chair.